If you or a loved one has recently been diagnosed with myelofibrosis, understanding the basics of the disease can be a helpful first step. While this article provides a general overview of myelofibrosis, it's important to consult with a healthcare professional for personalized guidance. For more in-depth information, consider exploring resources such as our 101 Myelofibrosis articles.
Myelofibrosis (MF) is a type of blood cancer that affects the bone marrow, the tissue inside bones that produces blood cells. In myelofibrosis, the bone marrow becomes scarred (fibrosis), which disrupts the production of normal blood cells. This can lead to several health issues, including anemia, an enlarged spleen (splenomegaly), and an enlarged liver (hepatomegaly).
Myelofibrosis is often driven by mutations in specific genes, most commonly JAK2, CALR, or MPL. These mutations cause abnormal signaling in the bone marrow cells, leading to excessive production of certain blood cells and inflammatory substances.
People with myelofibrosis may experience a range of symptoms that can impact their quality of life, including:
Myelofibrosis is a rare disease, affecting about 2 to 4 people per 100,000 worldwide and about 4 to 6 people per 100,000 in the United States.
Diagnosing myelofibrosis typically involves a series of tests, including:
Treatment for myelofibrosis depends on the severity of the disease and the patient’s symptoms. The main goal is to manage symptoms and slow the progression of the disease. Treatment options include:
Research shows that early treatment for myelofibrosis, especially when the patient is still at a lower-risk stage, can lead to better outcomes. Early treatment with JAK inhibitors has been shown to improve symptoms and reduce the size of the spleen more effectively than delaying treatment.
Living with myelofibrosis can be challenging due to the symptoms and the need for ongoing treatment. However, many patients find ways to manage their symptoms and maintain a good quality of life. Regular follow-ups with a healthcare provider, staying informed about new treatments, and connecting with support groups can be very helpful.
To stay informed about the latest developments in myelofibrosis research and treatment, we encourage you to sign up for our newsletter and register for our upcoming webinars. By connecting with others who have similar experiences, you can find support, share insights, and work together towards better outcomes.
SUBSCRIBE TO MYELOFIBROSIS NEWSLETTER
Sources:
If you or a loved one has recently been diagnosed with myelofibrosis, understanding the basics of the disease can be a helpful first step. While this article provides a general overview of myelofibrosis, it's important to consult with a healthcare professional for personalized guidance. For more in-depth information, consider exploring resources such as our 101 Myelofibrosis articles.
Myelofibrosis (MF) is a type of blood cancer that affects the bone marrow, the tissue inside bones that produces blood cells. In myelofibrosis, the bone marrow becomes scarred (fibrosis), which disrupts the production of normal blood cells. This can lead to several health issues, including anemia, an enlarged spleen (splenomegaly), and an enlarged liver (hepatomegaly).
Myelofibrosis is often driven by mutations in specific genes, most commonly JAK2, CALR, or MPL. These mutations cause abnormal signaling in the bone marrow cells, leading to excessive production of certain blood cells and inflammatory substances.
People with myelofibrosis may experience a range of symptoms that can impact their quality of life, including:
Myelofibrosis is a rare disease, affecting about 2 to 4 people per 100,000 worldwide and about 4 to 6 people per 100,000 in the United States.
Diagnosing myelofibrosis typically involves a series of tests, including:
Treatment for myelofibrosis depends on the severity of the disease and the patient’s symptoms. The main goal is to manage symptoms and slow the progression of the disease. Treatment options include:
Research shows that early treatment for myelofibrosis, especially when the patient is still at a lower-risk stage, can lead to better outcomes. Early treatment with JAK inhibitors has been shown to improve symptoms and reduce the size of the spleen more effectively than delaying treatment.
Living with myelofibrosis can be challenging due to the symptoms and the need for ongoing treatment. However, many patients find ways to manage their symptoms and maintain a good quality of life. Regular follow-ups with a healthcare provider, staying informed about new treatments, and connecting with support groups can be very helpful.
To stay informed about the latest developments in myelofibrosis research and treatment, we encourage you to sign up for our newsletter and register for our upcoming webinars. By connecting with others who have similar experiences, you can find support, share insights, and work together towards better outcomes.
SUBSCRIBE TO MYELOFIBROSIS NEWSLETTER
Sources:
about the author
Jimena Vicencio
Jimena is an International Medical Graduate and a member of the HealthTree Writing team. She has a passion for languages and is currently learning Japanese. In her free time, she loves playing with her cats. Jimena is also pursuing a bachelor's degree in journalism.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.